MedTrace Logo

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2015-02-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers

Conditions

  • Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis

Interventions

DRUG

R89674 (generic name not yet established)

Sponsors & Collaborators

  • Vistakon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jack V Greiner, OD, DO, PhD · Ophthalmic Research Associates, North Andover, MA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00223951 on ClinicalTrials.gov